Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Importance Blood-based biomarkers for Alzheimer disease (AD) are clinically available, but their value is not well understood in syndromes typically associated with frontotemporal lobar degeneration syndromes (FTLD). Objective To investigate the clinical importance and detectability of AD in FTLD-related neurodegenerative syndromes using 3 plasma biomarkers, phosphorylated tau 217 (p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). Design, setting, and participants This clinicopathological study took place at the University of California San Francisco Alzheimer Disease Research Center from August 2008 to July 2022. Autopsied individuals with clinical evaluation and neuropathological examination, diagnosed with clinical syndromes related to AD (n = 125), frontotemporal lobar degeneration (FTLD; n = 198), or cognitively unimpaired (CU) at the time of evaluation (n = 16) were included. Exposures AD-related or FTLD-related clinical syndromes or CU. Main outcomes and measures P-tau217, NfL, and GFAP were measured with single-molecule array (SIMOA). AD was defined as intermediate or high AD neuropathological change (ADNC) at autopsy. Clinical biomarker associations were evaluated using linear regressions. Imaging analyses used bayesian linear mixed-effects modeling. Results A total of 349 individuals (191 [55%] male; mean [SD] age at death, 72 [11] years) were included. AD was common in both AD-related syndromes (110/125 [88%]) and FTLD-related syndromes (45/198 [23%]). Neuropathological stage at autopsy was higher in AD-related syndromes (high ADNC: 82/88 [93%] AD vs 13/23 [56%] FTLD), and AD was frequently considered a copathology in FTLD-related syndromes (30/198 [15%]). Plasma p-tau217 concentrations were higher in AD-related syndromes (mean [SD], 0.28 [0.16] pg/mL) than FTLD-related syndromes (mean [SD], 0.10 [0.09] pg/mL) (P Conclusion Clinically relevant AD was prevalent across neurodegenerative syndromes and detectable with plasma p-tau217. Plasma p-tau217 may be a useful tool to investigate the clinical impact of AD copathology in non-AD neurodegenerative syndromes, including the effect of disease-modifying therapies.

What this study adds

Evidence grade: Low

The record lists 125 participants. This clinicopathological study measured three blood biomarkers (p-tau217, NfL, and GFAP) in 349 autopsied individuals, including people with syndromes usually linked to frontotemporal lobar degeneration. It examined whether these blood tests can detect Alzheimer's disease pathology in people whose clinical syndrome is not typical Alzheimer's, but the available summary does not report how well the biomarkers performed.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

VandeVrede, L., Cho, H., Sanderson-Cimino, M., Wekselman, F., Cobigo, Y., Gorno-Tempini, M. L., et al. (2025). Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers. JAMA neurology. https://doi.org/10.1001/jamaneurol.2024.5017

Vancouver

VandeVrede L, Cho H, Sanderson-Cimino M, Wekselman F, Cobigo Y, Gorno-Tempini ML, et al. Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers. JAMA neurology. 2025. doi:10.1001/jamaneurol.2024.5017. PMID: 39928343.

BibTeX

@article{vandevrede2025-39928343,
  author  = {VandeVrede, L. and Cho, H. and Sanderson-Cimino, M. and Wekselman, F. and Cobigo, Y. and Gorno-Tempini, M. L. and Heuer, H. W. and Kramer, J. H. and others},
  title   = {{Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers}},
  journal = {JAMA neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2024.5017},
  pmid    = {39928343},
  url     = {https://doi.org/10.1001/jamaneurol.2024.5017}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This clinicopathological study measured three blood biomarkers (p-tau217, NfL, and GFAP) in 349 autopsied individuals, including people with syndromes usually linked to frontotemporal lobar degeneration. It examined whether these blood tests can detect Alzheimer's disease pathology in people whose clinical syndrome is not typical Alzheimer's, but the available summary does not report how well the biomarkers performed.

Study details

How this study scored 59/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 5 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 59 of 100.59 of 100 points earned41 not earned

Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA neurology)
Journal's citation record 2 / 4 JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 125 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 57 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 19.0 citations a year over 3 year(s) since 2025
Impact for its field and year 5 / 6 Cited 36.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 7 other studies in this library
Still being cited 3 / 4 Cited 57 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Adam L. Boxer: h-index 98 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California, San Francisco: institution h-index 1,915 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39928343)
Free to read 2 / 2 Free to read
Total 59 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.

Later studies that cite this one

7 studies in the alzhub library list this one in their references.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →